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EDITORIAL 
"ALL ANTIDEPRESSANTS ARE CREATED EQUAL" 
(SOME ARE MORE EQUAL THAN OTHERS) 
"All antidepressants have a 60-70% 
response rate". "Nobody has ever proved that 
one antidepressant is better than another". 
How far are these statements true? Does 
this mean that antidepressants are 
interchangeable? 
All marketable drugs are categorized as 
belonging to a particular class depending upon 
specific biochemical or pharmacological 
properties. Grouping together drugs in this 
fashion has certain advantages and 
disadvantages. 
To assume that drugs belonging to a 
particular class can be used interchangeably may 
not be true. Interchangeability does not take into 
account the benefit, risk or cost of the drug. Drug 
selection within a class may depend on 
marketing strategies (Furberg et al.,1999). 
Drug regulating agencies assume that all 
drugs within a class are related by structure, 
activity or adverse effects. This assumption is 
qualitative i.e., whether the drug is effective when 
compared to standard drug or plecebo. The 
agency is not concerned with quantitative 
differences in terms of efficacy or safety. It is 
the marketing department, which often decides 
this issue. Certain drugs may have long term 
side effects, which become obvious only by post 
marketing surveillance or anecedotal reports by 
practitioners (pharmacovigilance). 
Why should an antidepressant be 
changed? 
The three main reasons are lack of 
efficacy, troublesome side effects, or the high 
cost of the drug 
Traditionally, antidepressants are 
classified into three group viz., tricyclic 
antidepressants (TCAs), selective serotonin 
reuptake inhibitors (SSRIs), and monoamine 
oxidse inhibitors (MAOIs). 
Drugs belonging to a particular group are 
supposedly interchangeable. But there are 
limitations. 
Dothiepin, doxepin and amitriptyline are 
all sedative tricyclic antidepressants If a 
switchover is made from dothiepin to doxepin 
or amitriptyline for some reason, there is a risk 
ofdeveloping acute urinary retention, or frequent 
falls and fractures because of marked 
anticholinergic and adrenargic side effects with 
amitriptyline and doxepin which can be 
disastrous (Kaplan & Sadock,1991). 
When changing over from a TCA to a 
SSRI, the SSRI may not prove as effective as 
the TCA (Preskorn,1994). TCAs are more 
effective than SSRIs, especially in severely 
depressed inpatients (DUAG, 1988; DUAG, 1990; 
Rooseetal.,1994; Anderson STomenson, 1994). 
Simultaneous administration of a TCA and a 
SSRI can increase the TCA levels and cause 
severe side effects like seizures or cardiotoxicity 
or a serotonergic syndrome during the change 
over period (Montgomery, 1998). 
In comparative drug trials between two 
drugs, the statistical conclusion "no significant 
difference between two groups" does not mean 
the two drugs are equally effective At periodic 
follow-up assessments during the trial, a patient 
on drug A' may say "Doctor I feel great, can I 
stop the pills?" In contrast, the patient on drug 
B' may say "Doctor, like that, I am alright, but -
—". This could mean that drug B' is probably 
not as effective as drug A'. The two drugs may 
be quantitatively different though statistically not 
different. Statistical significance is not the same 
thing as clinical efficacy. Inadequate recovery 
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or residual symptoms of depression after 
antidepressant treatment, is one of the chief 
reasons for treatment resistant depression and 
relapses 
Approximately 20% of patients on 
antiaecessant treatment wili develop side 
effects of which about 90Vr wi:f become 
trea'ment resistant if the same antidepressant 
is continued TCAs are more babie to produce 
side effects than SSRIs because of action on 
multiple receptor systems. SSRIs act 
predominately on a single receptor system A 
single dose of a TCA can produe 
pharmacological effects similar to a "cocktail" 
of various drugs. For instance, a 25 mg dose of 
amitnptyline can produce effects as if a 
combination of chlorpheniramine, 
benzodiazepine, desipramine sertraline, 
cimetidine. prazosin and quinidine had been 
administered (Preskorn, 1994) However it is 
naive to assume that a SSRI will have effect on 
the serotonin system alone It is not possible to 
modulate the serotonin system without 
modulating the norepinephrine system also, 
because of their anatomical and physiological 
proximity (Richelson 1994) So SSRIs also have 
their own side effects But they a
re a different 
set of side effects 
In the present state of knowledge, 
antidepressants can be continued indefinitely 
(Herschfield.1994) If there is a long-term side 
effect e g , tardive dyskinesia which can occur 
with amoxapine. a change over may be required 
(Hsm-Tung et al..2000j An SSRI would then be 
the antidepressant of choice because of minimal 
long-term side effects SSRIs especially 
fluoxetine can interfere with cytochrome enzyme 
P450 which is involved m the metabolism of 
several drugs, (De Vane 1994) The long term 
consequences of prolonged interference with 
cytochrome enzyme P450 are not known 
(Preskorn 1994) 
Medically compromised patients with 
depression are preferably treated with a SSRI 
because of the miia deg
ree of depression, and 
the minimal risk of side effects. Most of these 
patients are on polypharmacy Concurrent SSRI 
administration can create problems because of 
drug interactions, which would not be the case 
with TCAs (.Preskorn, 1994). 
With some SSRIs, prolonged 
administration may worsen the depressive 
symptoms through sensitization (Fava,1999) or 
induce tolerance requiring higher doses of the 
drug to produce the same effect (Lieb,1984) (a 
form of tachyphylaxis). Conversely, some TCAs 
may show tnerapeutic effects only after 
prolonged administration. This becomes relevant 
at time of switching over from one class of drugs 
to another 
it may be necessary to change over from 
an expensive antidepressant to less expensive 
one for economic reasons. In the long term the 
new drug may not be cost effective because of 
hidden expenses which were no? apparent 
initially The drug may have a delayed onset of 
action, may require several daily doses, may 
need constant monitoring or expensive 
investigations, may be difficult to obtain, or have 
high overdosage toxicity etc. The purchase price 
of the drug is by no means the only criterion for 
overall cost effectiveness 
Therefore, antidepressants should not be 
interchanged indiscriminately unless there are 
solid reasons like health benefit and long term 
safety .Most people are reluctant to change their 
barbers, their aentists or their spouses The same 
caution should be exercised when changing 
antidepressants. 
Dinshaw R. Ooongaji 
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